Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
22 Octobre 2024 - 8:00AM
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS),
a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, announced today that they will be showcasing
pre-clinical data that permit the design of an efficient and
specific TALE base editors (TALEB) as well as a process to enhance
the efficacy of non-viral gene insertion in hematopoietic stem and
progenitor cells (HSPCs) at the European Society of Cell and Gene
Therapy 31st annual congress, that will take place on October
22-25, 2024, in Roma, Italy.
The data will be presented in two posters:
Controlling C-to-T editing with TALE
base editors
Presenter: Alexandre Juillerat,
Ph.D., Vice-President Gene Editing & NY Lab Head at
Cellectis
Date/Time: Thursday, October 24
from 2:00pm to 3:30pm CET
Poster number: P0666
- TALE base editors (TALEB) are
fusions of a transcription activator-like effector domain (TALE),
split-DddA deaminase halves, and an uracil glycosylase inhibitor
(UGI). The C-to-T class of TALEB edits double strand DNA by
converting a cytosine (C) to a thymine (T) via the formation of an
uracil intermediate.
- Cellectis recently developed a
strategy that allows the comprehensive characterization of C-to-T
conversion efficiencies within the editing window. This method also
takes advantage of a highly precise and efficient TALEN®-mediated
ssODN knock-in in primary T cells to assess how target composition
and spacer variations affect TALEB activity/efficiency.
- The datasets obtained in this study
enhanced our understanding of TALEB and permitted the design of
efficient and specific tools that could be compatible with the
potential development of therapeutic applications.
Circular Single-Stranded DNA Enables
Efficient TALEN-Mediated Gene Insertion in Long Term
HSC
Presenter: Julien Valton,
Ph.D., Vice-President Gene Therapy at Cellectis
Date/Time: Thursday, October 24
from 2:00pm to 3:30pm CET
Poster number: P0585
- Non-viral alternatives such as
linear single-stranded DNA (LssDNA) and circular single-stranded
DNA (CssDNA) are emerging as promising options to vectorized DNA
donor template for nuclease-mediated gene insertion in
hematopoietic stem and progenitor cells (HSPCs) used for gene
therapy applications.
- Capitalizing on its TALEN®
technology, Cellectis has devised a gene editing process that
incorporates non-viral DNA donor template delivery (LssDNA or
CssDNA) to enhance gene insertion in HSPCs.
- The circularization of ssDNA
increases gene insertion rates in long term HSCs and has the
potential to enhance their engraftment capacity in preclinical
murine model, thereby to facilitate the advancement of
next-generation cell therapies. This research marks a crucial step
towards enhancing the efficacy of non-viral gene therapy.
The posters will be published on Cellectis’
website after the presentations.
About
Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with 25
years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
To find out more, visit our website:
www.cellectis.com
Follow Cellectis on social networks @cellectis
on LinkedIn and X (formerly Twitter)
TALEN® is a registered trademark owned by
Cellectis.
Forward-looking
Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
"will”, “could”, “potential”, “has the potential to” and emerging
or the negative of these and similar expressions. These
forward-looking statements, which are based on our management’s
current expectations and assumptions and on information currently
available to management, include statements about the potential of
our research programs, including without limitation the TALEB and
TALEN technologies. These forward-looking statements are made in
light of information currently available to us and are subject to
numerous risks and uncertainties, including with respect to the
numerous risks associated with biopharmaceutical product candidate
development. Furthermore, many other important factors, including
those described in our Annual Report on Form 20-F and the financial
report (including the management report) for the year ended
December 31, 2023 and subsequent filings Cellectis makes with the
Securities Exchange Commission from time to time, as well as other
known and unknown risks and uncertainties may adversely affect such
forward-looking statements and cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
For further information on Cellectis, please
contact:
Media
contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14
33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7
76 77 46 93
Investor Relations
contact:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809
5980, investors@cellectis.com
- PRESS RELEASE-ESGCT_POSTERS
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024